ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for drug discovery, pre-clinical safety, and efficacy screenings of novel compounds, operating worldwide.

ZeClinics has a global reach and yet a flexible approach; with corporate and academic clients across four continents and customized services for the Pharma, Biotech, Chemical, Cosmetic, and Food sectors. We at ZeClinics combine the strength of the zebrafish model with a highly diversified, cost-effective, and reliable portfolio.

Thanks to our high-throughput solutions, cutting-edge CRISPR/cas9 gene-editing, and tailored phenotypic assays we are able to reduce by 10-fold our clients’ time and cost requirements in early compound development.

With the sponsorship of the European Commission (Horizon2020 SME Instrument Phase II grant) and the support of the University Pompeu Fabra (UPF), ZeClinics spun off the dynamic environment of the Barcelona Biomedicine Research Park (PRBB). Our business strengths rely on high technical expertise and top-notch research facilities, combined with attractive strategic partnerships and academic collaborations. In a challenging economic environment, ZeClinics represents a fine example of a business model that embraces research and innovation as a way to success.

We offer three service areas:

- ZeTox: Combining acute, chronic, general and organ-specific high-throughput toxicology screenings.
- ZeGenesis: A CRISPR/Cas9-licensed platform for the generation of knock-out, knock-in, transgenic zebrafish or cell lines.
- ZeEfficacy: Ready-to-use and customized models for phenotypic screenings and early efficacy testing of large compound libraries.